In response to Authority requests to document the safety and efficacy of liraglutide (Victoza®) in children and adolescents with type 2 diabetes, Novo Nordisk has initiated a global clinical trial named "Ellipse" or NN2211-3659. To learn more about the trial, the participating countries and where to get more information, please follow the links below.

ClinicalTrials.gov

Clinical trials at Novo Nordisk

In a Company Announcement on 19th December 2012, Novo Nordisk reported three significant pipeline developments:

• Further development of ultra-rapid-acting insulin aspart (FIAsp:NN1218) into phase 3 development, following successful completion of phase 1 proof-of-concept trials
  
• Completion of IDegLira phase 3a program based on positive results from DUAL II and, earlier reported DUAL I, trials that document efficacy, safety and convenience of IDegLira in diabetes patients previously inadequately controlled on basal insulin plus 1-2 OADs at all stages of disease. IDegLira is a fixed-ratio combination of the ultra-long acting basal analogue, Tresiba (degludec), and the once-daily GLP-1 agonist, Victoza (liraglutide).
  
• Discontinuation of an inflammation project (NN8555) in phase 2a evaluation for Crohn's disease, due to immunogenicity findings
  

Read the company announcement 

Bagsværd, Denmark - Novo Nordisk was  ranked number four on the Science 2012 Top Employer list – up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.

Read the company announcement